Overview

A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

Status:
Completed
Trial end date:
2020-12-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if LY03005 is effective and safe in improve MADRS score, as compared to placebo (no medicine) in participants with Major Depressive Disorder (MDD)
Phase:
Phase 3
Details
Lead Sponsor:
Luye Pharma Group Ltd.